Market Closed -
Other stock markets
|
Pre-market 08:15:00 am | |||
74.38 USD | -1.31% | 73.42 | -1.30% |
May. 23 | Boston Scientific Insider Sold Shares Worth $2,504,239, According to a Recent SEC Filing | MT |
May. 23 | Medtronic beats quarterly profit estimates on medical devices strength | RE |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 50.55 and 41.07 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.66% | 109B | A- | ||
+10.22% | 223B | B | ||
+12.99% | 194B | B- | ||
+18.09% | 141B | B- | ||
+1.75% | 64.85B | A- | ||
+14.70% | 52.7B | B+ | ||
+6.68% | 51.77B | B+ | ||
+8.29% | 44.12B | A | ||
+2.60% | 36.21B | - | ||
+23.00% | 31.08B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BSX Stock
- Ratings Boston Scientific Corporation